2025 Q2 -tulosraportti
179 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
45 708
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenWill this just continue flat after some increase until Thursday 26? Or will we see a fall after such a big rise? What do you think will happen after the 26th? 😄
·1 t sittenWhen it is as cheap as it is, people will still want to be in before the big price adjustment on the 26th. So we will rise over 2kr before then 🤑🤠
13 t sitten13 t sitten
·18 t sittenSharing this on behalf of "CRNA" who published this on Tekinvestor. He is a top 10 shareholder who has been with the company for 3-4 years and has followed the company closely during this period. "As most here know, Circio has completed a successful and heavily oversubscribed private placement of 50 million kroner(was 68). This closed the door for the expensive and dilutive financing solutions (Atlas Capital Markets) that characterized 2025 and was the reason why any positive news did not affect the share price in the right direction. But the Atlas agreement saved the company during a terrible time for biotech where many companies went under. The capital the company has now raised secures operations through the important milestones in 2026. In 2025, the uncertainty surrounding cash reserves was a source of constant share price decline. Now the “Atlas Capital Markets”-financing has ended and convertible loans eliminated, which removes significant dilution fear. According to the company, they will now escalate activity on all fronts. I bet we will get disease models and ape studies reasonably quickly. Regarding the technology, Circio has developed circVec 4.0, which is expected to show further improvements in protein expression. The company is now working on and testing/focusing on improved tissue selectivity (especially heart and brain structure/CNS) and reduced liver accumulation. While 2025 was “does this work?”, 2026 is “how well does it work in complex diseases?”. This is what will be extremely exciting to get an answer to, and we will probably get pointers during the year. The company announced at the end of 2025 that they are starting a feasibility study with a large global pharmaceutical player. I have seen some talk this down, given that approx. 4 million is just pocket change for such a player. I agree with that assessment, but it is a clear signal that the technology is very exciting and attracts large players. The results from these studies are expected to materialize in 2026. A positive agreement here will serve as a quality stamp and can lead to licensing agreements (milestone payments), which gives a completely different valuation than in 2025. I recommend everyone who is somewhat interested in the company, the technology, or is considering investing in the company to look at the many articles and interviews with management and key personnel in the company that have been published in the last year (almost exclusively foreign media). Norwegian media, for some reason, shies away from this company. Whether this will be a success remains to be seen. I have faith and believe that last week we saw the beginning of Circio's repricing. I personally believe Circio's value will rise steadily throughout 2026. I also note that the company's largest shareholders have traded heavily over the counter even after he significantly pre-subscribed in the private placement. The company is now active on many fronts and, according to themselves, has many shots on goal, so let this be Norwegian biotech's Bodø/Glimt"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
179 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWill this just continue flat after some increase until Thursday 26? Or will we see a fall after such a big rise? What do you think will happen after the 26th? 😄·1 t sittenWhen it is as cheap as it is, people will still want to be in before the big price adjustment on the 26th. So we will rise over 2kr before then 🤑🤠
- 13 t sitten13 t sitten
- ·18 t sittenSharing this on behalf of "CRNA" who published this on Tekinvestor. He is a top 10 shareholder who has been with the company for 3-4 years and has followed the company closely during this period. "As most here know, Circio has completed a successful and heavily oversubscribed private placement of 50 million kroner(was 68). This closed the door for the expensive and dilutive financing solutions (Atlas Capital Markets) that characterized 2025 and was the reason why any positive news did not affect the share price in the right direction. But the Atlas agreement saved the company during a terrible time for biotech where many companies went under. The capital the company has now raised secures operations through the important milestones in 2026. In 2025, the uncertainty surrounding cash reserves was a source of constant share price decline. Now the “Atlas Capital Markets”-financing has ended and convertible loans eliminated, which removes significant dilution fear. According to the company, they will now escalate activity on all fronts. I bet we will get disease models and ape studies reasonably quickly. Regarding the technology, Circio has developed circVec 4.0, which is expected to show further improvements in protein expression. The company is now working on and testing/focusing on improved tissue selectivity (especially heart and brain structure/CNS) and reduced liver accumulation. While 2025 was “does this work?”, 2026 is “how well does it work in complex diseases?”. This is what will be extremely exciting to get an answer to, and we will probably get pointers during the year. The company announced at the end of 2025 that they are starting a feasibility study with a large global pharmaceutical player. I have seen some talk this down, given that approx. 4 million is just pocket change for such a player. I agree with that assessment, but it is a clear signal that the technology is very exciting and attracts large players. The results from these studies are expected to materialize in 2026. A positive agreement here will serve as a quality stamp and can lead to licensing agreements (milestone payments), which gives a completely different valuation than in 2025. I recommend everyone who is somewhat interested in the company, the technology, or is considering investing in the company to look at the many articles and interviews with management and key personnel in the company that have been published in the last year (almost exclusively foreign media). Norwegian media, for some reason, shies away from this company. Whether this will be a success remains to be seen. I have faith and believe that last week we saw the beginning of Circio's repricing. I personally believe Circio's value will rise steadily throughout 2026. I also note that the company's largest shareholders have traded heavily over the counter even after he significantly pre-subscribed in the private placement. The company is now active on many fronts and, according to themselves, has many shots on goal, so let this be Norwegian biotech's Bodø/Glimt"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
45 708
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
179 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWill this just continue flat after some increase until Thursday 26? Or will we see a fall after such a big rise? What do you think will happen after the 26th? 😄·1 t sittenWhen it is as cheap as it is, people will still want to be in before the big price adjustment on the 26th. So we will rise over 2kr before then 🤑🤠
- 13 t sitten13 t sitten
- ·18 t sittenSharing this on behalf of "CRNA" who published this on Tekinvestor. He is a top 10 shareholder who has been with the company for 3-4 years and has followed the company closely during this period. "As most here know, Circio has completed a successful and heavily oversubscribed private placement of 50 million kroner(was 68). This closed the door for the expensive and dilutive financing solutions (Atlas Capital Markets) that characterized 2025 and was the reason why any positive news did not affect the share price in the right direction. But the Atlas agreement saved the company during a terrible time for biotech where many companies went under. The capital the company has now raised secures operations through the important milestones in 2026. In 2025, the uncertainty surrounding cash reserves was a source of constant share price decline. Now the “Atlas Capital Markets”-financing has ended and convertible loans eliminated, which removes significant dilution fear. According to the company, they will now escalate activity on all fronts. I bet we will get disease models and ape studies reasonably quickly. Regarding the technology, Circio has developed circVec 4.0, which is expected to show further improvements in protein expression. The company is now working on and testing/focusing on improved tissue selectivity (especially heart and brain structure/CNS) and reduced liver accumulation. While 2025 was “does this work?”, 2026 is “how well does it work in complex diseases?”. This is what will be extremely exciting to get an answer to, and we will probably get pointers during the year. The company announced at the end of 2025 that they are starting a feasibility study with a large global pharmaceutical player. I have seen some talk this down, given that approx. 4 million is just pocket change for such a player. I agree with that assessment, but it is a clear signal that the technology is very exciting and attracts large players. The results from these studies are expected to materialize in 2026. A positive agreement here will serve as a quality stamp and can lead to licensing agreements (milestone payments), which gives a completely different valuation than in 2025. I recommend everyone who is somewhat interested in the company, the technology, or is considering investing in the company to look at the many articles and interviews with management and key personnel in the company that have been published in the last year (almost exclusively foreign media). Norwegian media, for some reason, shies away from this company. Whether this will be a success remains to be seen. I have faith and believe that last week we saw the beginning of Circio's repricing. I personally believe Circio's value will rise steadily throughout 2026. I also note that the company's largest shareholders have traded heavily over the counter even after he significantly pre-subscribed in the private placement. The company is now active on many fronts and, according to themselves, has many shots on goal, so let this be Norwegian biotech's Bodø/Glimt"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
45 708
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt